Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids: H. Koga, et al.; J. Med. Chem. 23, 1358 (1980) Abstract
Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections: K. Hirai, et al.; Antimicrob. Agents Chemother. 19, 188 (1981) Abstract; Full Text
In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa: J. Downs, et al.; Antimicrob. Agents Chemother. 21, 670 (1982) Abstract
Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents: H.H. Gadebusch, et al.; Infection 10, 41 (1982) Abstract
Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin: S.R. Crider, et al.; N. Engl. J. Med. 311, 137 (1984) Abstract
Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use: B. Holmes, et al.; Drugs 30, 482 (1985) Abstract
Norfloxacin: clinical pharmacology and clinical use: R.C. Rowen, et al.; Pharmacotherapy 7, 92 (1987) Abstract
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of norfloxacin in rats: M. Chenel, et al.; Antimicrob. Agents Chemother. 47, 1952 (2003) Abstract; Full Text
Norfloxacin-induced DNA gyrase cleavage complexes block Escherichia coli replication forks, causing double-stranded breaks in vivo: J.R. Pohlhaus & K.N. Kreuzer; Mol. Microbiol. 56, 1416 (2005) Abstract; Full Text
Anxiogenic potential of ciprofloxacin and norfloxacin in rats: S. Sen, et al.; Singapore Med. J. 48, 1028 (2007) Abstract; Full Text
|
